Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
OCUFLOX® (ofloxacin ophthalmic solution) 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use.
(±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6carboxylic acid.
 |
Contains: Active: ofloxacin 0.3% (3 mg/mL). Preservative: benzalkonium chloride (0.005%).
Inactives: sodium chloride and purified water. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.
OCUFLOX® solution is unbuffered and formulated with a pH of 6.4 (range -6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.
OCUFLOX® (ofloxacin) is indicated for the treatment of conjunctivitis when caused by susceptible strains of the following bacteria:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of OCUFLOX and other antibacterial drugs, OCUFLOX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.
Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of OCUFLOX in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use. See Pediatrics.
Geriatrics (> 65 years of age): No comparative data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.
Prolonged use of OCUFLOX may result in overgrowth of nonsusceptible organisms, including fungi. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If the infection is not improved within 7 days, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.
One to two drops every two to four hours for the first two days, and then four times daily in the affected eye(s) for 8 days.
Health Canada has not authorized an indication for pediatric use.
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures to avoid eye injury and contamination of the eye drops.
The preservative in OCUFLOX, benzalkonium chloride, may be absorbed by and cause discoloration of soft contact lenses. OCUFLOX should not be administered while wearing soft contact lenses. Contact lenses should be removed prior to instillation of OCUFLOX and may be reinserted 15 minutes following its administration.
Patients should be instructed to instill the drops as soon as they remember, and then to return to their regular routine.
Table 1 - Dosage Forms, Strengths, Composition and Packaging
| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
| ophthalmic | solution, 0.3% w/v | benzalkonium chloride 0.005% w/v (as preservative), hydrochloric acid and/or sodium hydroxide to adjust the pH, purified water and sodium chloride |
OCUFLOX is available for topical ophthalmic administration as a 0.3% w/v sterile solution in the unopened package and is supplied in plastic dropper bottles of 5 mL.
AbbVie Corporation, 8401 Trans-Canada Highway, St-Laurent, Quebec, H4S 1Z1. Revised: Aug 2022
Since a small amount of ofloxacin is systemically absorbed after topical administration, adverse reactions reported with systemic use could possibly occur.
The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions were ocular irritation, redness, stinging, itching, photophobia, tearing and dryness. One report of dizziness, one report of headache and one spontaneous report of toxic epidermal necrolysis have also been received.
As with all topical ophthalmic drugs, the potential exists for systemic effects. Ofloxacin used systemically has rarely been associated with serious side effects. Serious reactions reported for systemic dosing of ofloxacin include convulsions and increased intracranial pressure. For the oral dosage form of ofloxacin, gastrointestinal symptoms, mainly nausea/vomiting, pain/discomfort, diarrhea and anorexia, were reported most frequently, followed by central nervous system events (such as dizziness and headaches) and dermatological or hypersensitivity reactions. Additional effects OCUFLOX (ofloxacin) seen with systemic dosing of ofloxacin and other fluoroquinolones are QT prolongation, exacerbation of myasthenia gravis symptoms, tendinitis and tendon rupture. Photophobia was reported rarely in clinical trials with systemic ofloxacin and phototoxicity has been reported with other drugs in this class.
The following adverse reactions have been identified during post marketing use of OCUFLOX in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.
Eye disorders: Conjunctivitis, dry eye, eye edema, eye pain, foreign body sensation in eyes, hypersensitivity (including eye pruritus, eyelids pruritus), keratitis, lacrimation increased, ocular hyperemia, periorbital edema (including eyelid edema), photophobia, vision blurred.
Gastrointestinal disorders: Nausea
Immune system disorders: Hypersensitivity (including angioedema, dyspnea, anaphylactic reaction/shock, oropharyngeal swelling, facial edema, Stevens-Johnson syndrome, tongue swollen, and toxic epidermal necrolysis).
Nervous system disorders: Dizziness
Specific drug interaction studies have not been conducted with OCUFLOX.
No formal drug-behavioural interaction studies were conducted with OCUFLOX.
No formal drug-drug interaction studies were conducted with OCUFLOX.
Interactions with food have not been established.
Interactions with herbal products have not been established.
Interactions with laboratory tests have not been established.
Included as part of the PRECAUTIONS section.
OCUFLOX is not for injection into the eye.
Contact of the tip of the dispensing container with the eye or surrounding structures may lead to eye injury and contamination of eye drops.
The use of ofloxacin with other products may lead to drug interactions. For established or potential drug interactions. See DRUG INTERACTIONS.
As with any ocular medication, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.
Use OCUFLOX with caution in patients who have exhibited sensitivities to other quinolone antibacterial agents. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions may require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids and airway management, including intubation, should be administered as clinically indicated. OCUFLOX should be discontinued if an allergic reaction occurs.
Hypersensitivity reactions including angioedema, dyspnea, anaphylactic reaction/shock, oropharyngeal swelling, Stevens-Johnson syndrome, tongue swollen and toxic epidermal necrolysis have been reported with OCUFLOX. See Post-Market Adverse Reactions.
In patients receiving systemic quinolone therapy, serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching.
Tendon inflammation and rupture may occur with systemic fluoroquinolone therapy including ofloxacin, particularly in elderly patients and in those treated concurrently with corticosteroids. Treatment with OCUFLOX should be discontinued at the first sign of tendon inflammation.
The systemic administration of quinolones has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species. Ofloxacin, administered systemically at 10 mg/kg/day in young dogs (equivalent to 150 times the maximum recommended daily adult ophthalmic dose), has been associated with these types of effects.
Corneal precipitates, and corneal perforation in patients with pre-existing corneal epithelial defect/corneal ulcer, have been reported during treatment with topical ophthalmic ofloxacin. However, a causal relationship has not been established.
Prescribing OCUFLOX in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant organisms. See Dosing Considerations.
There have been no adequate and well-controlled studies performed in pregnant women. Since systemic quinolones have been shown to cause arthropathy in immature animals, OCUFLOX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Because ofloxacin taken systemically is excreted in breast milk, and there is potential for harm to nursing infants, a decision should be made whether to temporarily discontinue nursing during therapy or not to administer the drug, taking into account the importance of the drug to the mother.
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (> 65 years of age): No comparative data are available with topical ofloxacin therapy in this age category versus other age groups.
In the event of accidental ingestion of 10 mL of OCUFLOX, 30 mg of ofloxacin would be ingested. Although this amount may not be clinically significant in terms of overdosage, there could be an increased potential for systemic reactions.
A topical overdosage of OCUFLOX is considered a remote possibility. Discontinue medication if heavy or protracted use is suspected. In the event of a topical overdose, flush the eye with a topical ocular irrigant. For management of a suspected drug overdose, including accidental ingestion, contact your regional Poison Control Centre.
For management of a suspected drug overdose, including accidental ingestion, contact your regional Poison Control Centre.
OCUFLOX is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Dosage Forms, Strengths, Composition And Packaging. A history of hypersensitivity to other quinolones also contraindicates use of ofloxacin.
Table 1 : Dosage Forms, Strengths, Composition and Packaging
| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
| ophthalmic | solution, 0.3% w/v | benzalkonium chloride 0.005% w/v (as preservative), hydrochloric acid and/or sodium hydroxide to adjust the pH, purified water and sodium chloride |
OCUFLOX is available for topical ophthalmic administration as a 0.3% w/v sterile solution in the unopened package and is supplied in plastic dropper bottles of 5 mL.
The primary mechanism of action of ofloxacin appears to be the specific inhibition of DNA gyrase (topoisomerase II). This enzyme is responsible for the negative supercoiling of bacterial DNA and OCUFLOX (ofloxacin) consequently for its topological configuration, governing functions such as RNA transcription, protein synthesis, DNA replication and repair functions.
The general pharmacological activities of ofloxacin have been studied in several mammalian species. At the maximum therapeutic dose levels, no effects on the central nervous system, cardiovascular and respiratory system, autonomic response or smooth and skeletal muscle were observed. These results are consistent with the infrequent occurrence of serious adverse effects with systemic clinical use of ofloxacin. Any pharmacological effects observed were frequently associated with doses at least 1000 times the anticipated maximal daily ocular dose.
Systemic Pharmacokinetics
Absorption
In systemic pharmacokinetic studies following oral dosing, ofloxacin was rapidly absorbed into the blood stream, with peak serum concentrations (Cmax) increasing in a dose-related manner. There was no significant increase in peak serum ofloxacin concentration following multiple oral administrations.
Following administration of 0.3% ofloxacin topically 4 times daily to the eyes of 30 normal healthy adults, mean serum plateau levels of 0.97 ng/mL after the first dose (day 1) and 1.66 ng/mL after the 41st dose (day 11) were achieved. The maximum serum level from multiple topical dosing (1.9 ng/mL) was approximately 2000-fold less than the maximum serum level achieved from treatment with a single 300 mg oral dose (4620 ng/mL). Time to reach 90% of the plateau serum concentration was 0.9 hours after the initial dose on Day 1 compared with 0.5 hours on Day 11, indicating a change in the rate of systemic absorption from ophthalmic dosing.
Metabolism And Elimination
The metabolism of ofloxacin was studied in five healthy adult male volunteers receiving a single oral dose of a 600 mg mixture of ofloxacin and deuterium-labeled ofloxacin. Ofloxacin and its metabolites were identified, confirmed and quantified using thin layer chromatography, UV spectrophotometry, high pressure liquid chromatography, fluorometry and other methods. Urinary concentration of ofloxacin increased to a maximum of 686.6 mcg/mL at 2-4 hours after dosing and was maintained above 273.9 mcg/mL 4-24 hours after dosing.
Cumulative urinary excretion of ofloxacin was 79.5% at 48 hours after dosing. Urinary concentrations of desmethyl ofloxacin were 10.4 and 6.6 mcg/mL at 2-4 and 12-24 hours after dosing, concentrations of ofloxacin N-oxide were 7.8 and 2.7 mcg/mL at 2-4 and 12-24 hours after dosing. Urinary concentrations of these metabolites were less than 2.5% of the excreted concentration of ofloxacin at each time interval.
The results of this study indicate that ofloxacin exists mainly as parent drug in vivo, and is excreted mainly unchanged in the urine in humans.
Ocular Pharmacokinetics
Absorption
Administering 0.3% ofloxacin topically 4 times daily to the eyes of 30 normal healthy adults resulted in tear ofloxacin concentrations ranging from 1.2 to 22 mcg/g (mean 9.2 mcg/g) four hours after the first dose on the eleventh day of treatment. The mean tear concentration varied between 5.7 and 31 mcg/g during the time period between 5 and 40 minutes after instillation of the second dose on day 11.
OCUFLOX is sterile in the unopened package, and is stable for 24 months when stored at 15 to 25°C. Keep bottle tightly closed when not in use.
Keep out of reach and sight of children.
There are no special handling instructions.
PrOCUFLOX®
Ofloxacin ophthalmic solution  Solution, 0.3% w/v, for ophthalmic use  USP
Antibacterial Agent (ATC code: S01AE01)
No clinical trial information is available for this product.
Ofloxacin has in vitro activity against both gram-positive and gram-negative organisms. The primary mechanism of action of ofloxacin appears to be the specific inhibition of DNA gyrase (topoisomerase II). This enzyme is responsible for the negative supercoiling of bacterial DNA and consequently for its topological configuration, governing functions such as RNA transcription, protein synthesis, DNA replication and repair functions.
In a four-site study using a modified tube-dilution procedure, the in vitro activity of ofloxacin was evaluated against 419 ocular bacterial isolates of 55 species, in media supplemented with Ca++ and Mg++. Table 2 includes MIC values for five major ocular pathogens.
Table 2 : In Vitro Antibacterial Activity of Ofloxacin Against Five Major Ocular Pathogens in Studies Conducted in the USA
| Minimum Inhibitory Concentration Range (mcg /mL) | |||
| ORGANISMS (Number) | MINIMUM | MAXIMUM | MIC90 |
| Staphylococcus aureus (79)1 | 0.125 | 4 | 0.5 |
| Staphylococcus epidermidis (68) | 0.125 | 16 | 0.5 |
| Pseudomonas aeruginosa (68) | 0.25 | 8 | 4 |
| Streptococcus pneumoniae (21) | 0.125 | 2 | 2 |
| Haemophilus influenzae (18) | 0.25 | 4 | 4 |
| 1 Number of isolates in parentheses. | |||
An in vitro evaluation of the activity (MIC) of ofloxacin was conducted using a broth dilution technique, with 2,678 organisms cultured from the infected eyes of subjects enrolled in three clinical trials conducted in the clinics of public hospitals in Japan. The minimum concentrations necessary to inhibit 90% of the strains (MIC90) was 3.13 mcg/mL or less for all species tested except various Pseudomonas species and for Streptococcus sanguis isolates. MIC90 values for ocular isolates are listed in Table 3.
Table 3 : Ocular Isolates from Japanese Clinical Studies (Ofloxacin MIC90 Values)
| Bacterial species | N | MIC90 (mcg/mL) |
| Acinetobacter var. anitratum | 44 | 0.39 |
| Acinetobacter var. lwoffii | 33 | 0.39 |
| Alcaligenes denitrificans | 10 | 1.56 |
| Alcaligenes faecalis | 24 | 0.78 |
| Bacillus species | 111 | 0.20 |
| Corynebacterium species | 379 | 3.13 |
| Enterobacter species (3: cloacae, aerogenes and agglomerans) | 44 | 0.20 |
| Escherichia coli | 8 | 0.10 |
| Flavobacterium species | 22 | 3.13 |
| Haemophilus aegyptius | 59 | 0.20 |
| Haemophilus influenzae | 44 | 0.20 |
| Klebsiella species (3: oxytoca, pneumoniae and ozaenae) | 21 | 0.10 |
| Micrococcus species | 73 | 1.56 |
| Moraxella species | 25 | 0.20 |
| Propionibacterium acnes | 66 | 1.56 |
| Proteus species (5: including mirabilis, vulgaris and morganii) | 30 | 0.20 |
| Pseudomonas acidovorans | 21 | 1.56 |
| Pseudomonas aeruginosa | 11 | 1.56 |
| Pseudomonas alcaligenes | 32 | 3.13 |
| Pseudomonas cepacia | 75 | 1.56 |
| Pseudomonas fluorescens | 44 | 0.78 |
| Pseudomonas maltophilia | 36 | 3.13 |
| Pseudomonas paucimobilis | 31 | 0.39 |
| Pseudomonas putida | 29 | 0.78 |
| Pseudomonas species (6: including vescularis and diminuta) | 16 | 50.5 |
| Pseudomonas stutzeri | 20 | 0.78 |
| Serratia marcescens | 46 | 0.39 |
| Staphylococcus aureus | 335 | 0.39 |
| Staphylococcus epidermidis | 735 | 0.39 |
| Streptococcus beta-hemolytic | 17 | 1.56 |
| Streptococcus faecalis (Enterococcus faecalis) | 14 | 1.56 |
| Streptococcus pneumoniae | 101 | 3.13 |
| Streptococcus sanguis | 96 | 6.25 |
| Streptococcus species (inc. pyogenes) | 35 | 3.13 |
Ofloxacin is bactericidal (3 log reduction in 1-2 hours) at 1 to 4 times the MIC.
Laboratory results from standard single disc susceptibility tests with a 5 mcg ofloxacin disc should be interpreted according to the following criteria:
| Zone Diameter (mm) | Interpretation |
| ≥ 16 | Susceptible |
| 13-15 | Moderately susceptible |
| ≤ 12 | Resistant |
The development of resistance to ofloxacin appears to be related to modification of bacterial DNA gyrase or to permeability changes in the bacterial outer cell membrane. Resistance to ofloxacin in vitro usually develops slowly (multiple-step mutation). Plasmid-mediated resistance or enzymatic inactivation have not been reported. Cross resistance among the fluoroquinolones has been observed, but development of clinically significant cross resistance to nonquinolone drugs appears to be uncommon.
Ofloxacin was administered in repeated doses in rats, dogs and monkeys for periods of up to 52 weeks. The most notable effect seen in these studies was the effect of ofloxacin on articular cartilage in immature animals. Several special studies of the effects of ofloxacin on articular cartilage were conducted. Orally administered ofloxacin had no effect on articular cartilage in mature rats and dogs. However, in immature animals, daily treatment for 7 days with ofloxacin at 300 mg/kg (but not at 100 mg/kg) in rats and at 10 mg/kg (but not at 5 mg/kg) in dogs produced arthropathic effects.
Studies were conducted to elucidate the mechanism of action, onset, recovery and effects of age and dosage on arthropathy associated with ofloxacin and other quinolones. The studies indicate that toxicity to weight-bearing joints is dose-related at oral dosages far higher than topical ophthalmic dosages and that toxic effects are seen only in growing animals. Damage to joints was partially repairable, although some damage appeared to be permanent. Damage such as erosion of the cartilage occurs in weight-bearing joints where “bubbles” (inconsistencies in growth) have developed in the cartilage.
Because ophthalmic ofloxacin solution is not intended for chronic use, specific carcinogenicity studies were not carried out. Chronic ophthalmic toxicity studies showed no evidence of carcinogenic potential.
Predictive tests included: Ames test, REC-Assay, micronucleus test, sister chromatid exchange in cultured Chinese hamster cells and in human peripheral blood lymphocytes, unscheduled DNA repair synthesis test, dominant lethal assay, and in vitro and in vivo cytogenetic tests.
Extensive tests for mutagenicity showed no mutagenic potential. Mutagenicity tests were conducted with ofloxacin by a number of techniques, both in vitro and in vivo. Dose-related damage to the DNA of Bacillus subtilis was seen in tests using the REC assay technique. The damage to B. subtilis DNA is consistent with the mechanism of action of the drug in bacteria and is not predictive of mutagenic potential in eukaryotic cells. No evidence of significant mutagenic effects was seen in other tests in a variety of eukaryotic somatic or germ cells.
Human blood samples were examined after oral dosing with 200 mg/day of ofloxacin for 1 to 10 weeks (equivalent to 50 times the maximum recommended daily ophthalmic dose). No chromosome-damaging effect was seen in the peripheral blood leukocytes.
The effects of ofloxacin on fertility, reproduction and fetal toxicity were studied in rats and rabbits. No adverse effects on fertility and general reproductive performance were seen in male or female rats from administration of ofloxacin in dosages of 10 mg/kg/day to 360 mg/kg/day, beginning well before mating and continuing through the seventh day of gestation in females.
Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/day (equivalent to 13500 times the maximum recommended daily ophthalmic dose) and 160 mg/kg/day (equivalent to 2600 times the daily ophthalmic dose) when administered to pregnant rats and rabbits, respectively. Additional studies in rats with doses up to 360 mg/kg/day during late gestation showed no adverse effect on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn. Doses of 810 mg/kg/day and 160 mg/kg/day resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively. Minor fetal skeletal variations were reported in rats receiving doses of 810 mg/kg/day.
Ocular toxicity studies were conducted in rabbits and monkeys with ofloxacin ophthalmic solutions. Results indicate that ofloxacin ophthalmic solutions are not toxic to the eyes under the conditions tested, including dosing up to 16 times per day. No local or systemic toxicity was observed as a result of ocular administration of ofloxacin for up to six months in rabbits or monkeys.
No evidence of ototoxicity, antigenicity or skin sensitization was seen in guinea pigs. Studies in rabbits revealed no evidence of nephrotoxicity.
Special studies of tissue distribution and accumulation, with special reference to the eye tissues, were conducted due to the tendency of ofloxacin to bind to the pigment melanin, which is present in some ocular structures. Studies with the topical solution showed definite binding to melanin which decreased slowly after withdrawal of the drug. In vitro studies with bovine melanin showed the affinity of ofloxacin for melanin to be greater than that of timolol and pilocarpine, but less than that of chloroquine and befunolol. The binding was reversible. A four-week study in pigmented rats revealed no evidence of ocular toxicity after daily oral doses of 100 mg/kg/day. Results of this study were consistent with the lack of ocular toxicity seen in multi-dose ocular and systemic toxicity studies in dogs and monkeys.
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PrOCUFLOX®
Ofloxacin ophthalmic solution
Read this carefully before you start taking OCUFLOX and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about OCUFLOX.
What is OCUFLOX used for?
Antibacterial drugs like OCUFLOX treat only bacterial infections. They do not treat viral infections.
How does OCUFLOX work?
OCUFLOX interferes with the bacterial growth and division. This helps stop the infection.
What are the ingredients in OCUFLOX?
Medicinal ingredient: Ofloxacin
Non-medicinal ingredients: Benzalkonium chloride 0.005% w/v (as preservative), hydrochloric acid and/or sodium hydroxide (to adjust the pH), purified water, sodium chloride.
OCUFLOX comes in the following dosage forms:
Ophthalmic solution, 0.3% w/v
Do not use OCUFLOX if:
To help avoid side effects and ensure proper use, talk to your healthcare professional before you take OCUFLOX. Talk about any health conditions or problems you may have, including if you:
Other warnings you should know about:
If you develop pain or swelling in your tendons, stop using OCUFLOX and get immediate medical help. This is more likely to happen if you are elderly or taking corticosteroids at the same time as OCUFLOX.
Changes in Vision:
Using OCUFLOX may temporarily blur your vision. Do not drive or use machines until your vision has cleared.
Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.
There are no known relevant interactions at this time.
How to take OCUFLOX:
Follow these steps to use OCUFLOX properly:
 |
Usual dose
One to two drops every two to four hours for the first two days. Then four times daily in the affected eye(s) for 8 days.
Overdose
If you have placed too many drops in your eye(s), wash the eye(s) with clean water. Apply your next dose at the normal time.
If you think you, or a person you are caring for, have taken too much OCUFLOX, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.
Missed dose
If you forget to apply your eye drops at your normal time, simply apply them as soon as you remember. Then go back to the original schedule as directed by your healthcare professional. Don’t try to catch up on missed drops by applying more than one dose at a time.
What are possible side effects from using OCUFLOX?
These are not all the possible side effects you may have when taking OCUFLOX. If you experience any side effects not listed here, tell your healthcare professional.
You should talk to your healthcare professional if any of the following side effects that affect the eye(s) prove troublesome or if they are long lasting:
You should talk to your healthcare professional if any of the following side effects that affect the body prove troublesome or if they are long-lasting:
Serious side effects and what to do about them
| Serious side effects and what to do about them | |||
| Symptom / effect | Talk to your healthcare professional | Stop taking drug and get immediate medical help | |
| Only if severe | In all cases | ||
| UNKNOWN | |||
| Severe allergic reaction: swelling of the mouth, throat, tongue or hands and feet, difficulty in breathing, skin reactions (redness, irritation, blistering, peeling), loss of consciousness or collapse | √ | ||
| Toxic epidermal necrolysis (severe skin reaction): redness, blistering and/or peeling of large areas of the skin | √ | ||
If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.
Reporting Side Effects
You can report any suspected side effects associated with the use of health products to Health Canada by:
NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.
Storage
OCUFLOX should be stored between 15 to 25°C. The bottle should be tightly closed when not in use.
Keep out of reach and sight of children.
If you want more information about OCUFLOX:
